Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer.

Autor: Zhang D; Pfizer Inc., 21717 30th Dr SE, Bothell, WA, 98021, USA., Taylor A; Integrated Drug Development, Certara USA, Princeton, NJ, USA., Zhao JJ; Integrated Drug Development, Certara USA, Princeton, NJ, USA., Endres CJ; Pfizer Inc., 21717 30th Dr SE, Bothell, WA, 98021, USA.; Immunome, Exton, PA, USA., Topletz-Erickson A; Pfizer Inc., 21717 30th Dr SE, Bothell, WA, 98021, USA. Ariel.Erickson@pfizer.com.
Jazyk: angličtina
Zdroj: Clinical pharmacokinetics [Clin Pharmacokinet] 2024 Oct; Vol. 63 (10), pp. 1477-1487. Date of Electronic Publication: 2024 Oct 05.
DOI: 10.1007/s40262-024-01412-0
Abstrakt: Background and Objective: Tucatinib is a highly selective, oral, reversible, human epidermal growth factor receptor 2 (HER2)-specific tyrosine kinase inhibitor. Tucatinib is approved at a 300-mg twice-daily dose in adults in combination with trastuzumab and capecitabine for advanced HER2-postitive (HER2+) unresectable or metastatic breast cancer and in combination with trastuzumab for RAS wild-type HER2+ unresectable or metastatic colorectal cancer. This study sought to characterize the pharmacokinetics (PK) and assess sources of PK variability of tucatinib in healthy volunteers and in patients with HER2+ metastatic breast or colorectal cancers.
Methods: A population pharmacokinetic model was developed based on data from four healthy participant studies and three studies in patients with either HER2+ metastatic breast cancer or metastatic colorectal cancer using a nonlinear mixed-effects modeling approach. Clinically relevant covariates were evaluated to assess their impact on exposure, and overall model performance was evaluated by prediction-corrected visual predictive checks.
Results: A two-compartment pharmacokinetic model with linear elimination and first-order absorption preceded by a lag time adequately described tucatinib pharmacokinetic profiles in 151 healthy participants and 132 patients. Tumor type was identified as a significant covariate affecting tucatinib bioavailability and clearance, resulting in a 1.2-fold and 2.1-fold increase in tucatinib steady-state exposure (area under the concentration-time curve) in HER2+ metastatic colorectal cancer and HER2+ metastatic breast cancer, respectively, compared with healthy participants. No other covariates, including mild renal or hepatic impairment, had an impact on tucatinib pharmacokinetics.
Conclusions: The impact of statistically significant covariates identified was not considered clinically meaningful. No tucatinib dose adjustments are required based on the covariates tested in the final population pharmacokinetic model.
Clinical Trial Registration: NCT03723395, NCT03914755, NCT03826602, NCT03043313, NCT01983501, NCT02025192.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: